| Ident. | Authors (with country if any) | Title |
|---|
| 001073 |
Anthony H. V. Schapira [Royaume-Uni] | The Clinical Relevance of Levodopa Toxicity in the Treatment of Parkinson's Disease |
| 001539 |
Martin Niethammer [États-Unis] ; Blair Ford [États-Unis] | Permanent lithium-induced cerebellar toxicity : Three cases and review of literature |
| 001A84 |
Katie Kompoliti [États-Unis] ; Christopher G. Goetz [États-Unis] ; Mary Morrissey [États-Unis] ; Sue Leurgans [États-Unis] | Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects |
| 001D23 |
Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis] | Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations |
| 001D54 |
Katherine Widnell [États-Unis] | Pathophysiology of motor fluctuations in Parkinson's disease |
| 001D68 |
Cheryl Waters [États-Unis] | Other pharmacological treatments for motor complications and dyskinesias |
| 001D92 |
Joseph Jankovic [États-Unis] | Motor fluctuations and dyskinesias in Parkinson's disease : Clinical manifestations |
| 002236 |
Brian K. Lassinger [États-Unis] ; Carolyn Kwak [États-Unis] ; Roy L. Walford [États-Unis] ; Joseph Jankovic [États-Unis] | Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: A possible complication of chronic hypoxia and carbon monoxide toxicity? |
| 002297 |
John M. Walshe [Royaume-Uni] | The story of penicillamine: A difficult birth |
| 002342 |
Padraig O'Suilleabhain [États-Unis] ; Cole Giller [États-Unis] | Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs |
| 002345 |
Charles H. Adler [États-Unis] ; John N. Caviness [États-Unis] ; Joseph G. Hentz [États-Unis] ; Marlene Lind [États-Unis] ; Judy Tiede [États-Unis] | Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease |
| 002383 |
Ali Samii [États-Unis] ; Debra D. Dahlen [États-Unis] ; Alexander M. Spence [États-Unis] ; Nicole C. Maronian [États-Unis] ; Eric E. Kraus [États-Unis] ; Vanda A. Lennon [États-Unis] | Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody |
| 002387 |
Claudia Trenkwalder [Allemagne] ; Victor Collado Seidel [Allemagne] ; Jörg Kazenwadel [Suisse] ; Thomas C. Wetter [Allemagne] ; Wolfgang Oertel [Allemagne] ; Roland Selzer [Allemagne] ; Ralf Kohnen [Allemagne] | One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome? |
| 002450 |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
| 002465 |
Kathy Steece-Collier [États-Unis] ; Timothy J. Collier [États-Unis] ; Paul D. Danielson [États-Unis] ; Roger Kurlan [États-Unis] ; David M. Yurek [États-Unis] ; John R. Jr Sladek [États-Unis] | Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats |
| 002500 |
Eduardo Tolosa [Espagne] ; Miguel Coelho [Espagne] ; Marisol Gallardo [Espagne] | DAT imaging in drug-induced and psychogenic parkinsonism |
| 002514 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 002518 |
Cathy Chuang [États-Unis] ; Anne Constantino [États-Unis] ; Casilda Balmaceda [États-Unis] ; David Eidelberg [États-Unis] ; Steven J. Frucht [États-Unis] | Chemotherapy-induced Parkinsonism responsive to levodopa: An underrecognized entity |
| 002519 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 002532 |
Noël L. W. Keijsers [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] ; Stan C. A. M. Gielen [Pays-Bas] | Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks |
| 002535 |
Isabelle Benatru [France] ; Stéphane Thobois [France] ; Nathalie Andre-Obadia [France] ; Pierre-Marie Gonnaud [France] ; Yara Beaugendre [France] ; Colette Berger [France] ; Michel Gonce [Belgique] ; Emmanuel Broussolle [France] | Atypical propriospinal myoclonus with possible relationship to α interferon therapy |
| 002539 |
Georg Ebersbach [Allemagne] | An artist's view of drug-induced hallucinosis |
| 002543 |
Christian Prueter [Allemagne] ; Benedikt Habermeyer [Allemagne] ; Christine Norra [Allemagne] ; Christoph M. Kosinski [Allemagne] | Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease |
| 002574 |
| Treatment of depression in idiopathic Parkinson's disease |
| 002577 |
Annie Lannuzel [France] ; Patrick P. Michel [France] ; Dominique Caparros-Lefebvre [France] ; Jacqueline Abaul [France] ; Reynald Hocquemiller [France] ; Merle Ruberg [France] | Toxicity of annonaceae for dopaminergic neurons: Potential role in atypical parkinsonism in Guadeloupe |
| 002584 |
Sujana Reddy [États-Unis] ; Stewart A. Factor [États-Unis] ; Eric S. Molho [États-Unis] ; Paul J. Feustel [États-Unis] | The effect of quetiapine on psychosis and motor function in Parkinsonian patients with and without dementia |
| 002589 |
Daniel Tarsy [États-Unis] ; Gerald Indorf [États-Unis] | Tardive tremor due to metoclopramide |
| 002664 |
Hélio A. G. Teive [Brésil] ; Francisco M. B. Germiniani [Brésil] ; Lineu César Werneck [Brésil] | Parkinsonian syndrome induced by amlodipine: Case report |
| 002704 |
Elena Meseguer [Espagne] ; Rocio Taboada [Espagne] ; Vicenta Sanchez [Espagne] ; Maria Angeles Mena [Espagne] ; Victor Campos [Espagne] ; Justo Garcia De Yebenes [Espagne] | Life-threatening parkinsonism induced by Kava-Kava |
| 002705 |
| Levodopa |
| 002707 |
Gurutz Linazasoro [Espagne] ; Nadege Van Blercom [Espagne] ; Asier Lasa [Espagne] | Levodopa-induced ocular dyskinesias in Parkinson's disease |
| 002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
| 002765 |
J. Carsten Moller [Allemagne] ; Karin Stiasny [Allemagne] ; Volker Hargutt [Allemagne] ; Werner Cassel [Allemagne] ; Heiko Tietze [Allemagne] ; J. Hermann Peter [Allemagne] ; H.-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: A pilot study |
| 002770 |
Alexander Fisher [Australie] ; James Croft-Baker [Australie] ; Michael Davis [Australie] ; Patrick Purcell [Australie] ; Allan J. Mclean [Australie] | Entacapone-induced hepatotoxicity and hepatic dysfunction |
| 002788 |
| Drugs to treat gastrointestinal motility problems |
| 002789 |
| Drugs to treat dementia and psychosis |
| 002790 |
| Drugs to treat autonomic dysfunction in Parkinson's disease |
| 002797 |
J. E. Rice [Australie] ; R. Antic [Australie] ; Philip D. Thompson [Australie] | Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease |
| 002808 |
| DA agonists: ergot derivatives: Bromocriptine |
| 002809 |
| DA agonists: Non-Ergot derivatives: Ropinirole |
| 002810 |
| DA agonists: Non-Ergot derivatives: Pramipexole |
| 002811 |
| DA agonists: Non-Ergot derivatives: Piribedil |
| 002812 |
| DA agonists: Non-Ergot derivatives: Apomorphine |
| 002813 |
| DA agonists: Ergot derivatives: Pergolide |
| 002814 |
| DA agonists: Ergot derivatives: Lisuride |
| 002815 |
| DA agonists: Ergot derivatives: Dihydroergocryptine (DHEC) |
| 002816 |
| DA agonists: Ergot derivatives: Cabergoline |
| 002839 |
| COMT inhibitors |
| 002842 |
Dirk Dressler [Royaume-Uni] ; Hans Bigalke [Allemagne] | Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy |
| 002851 |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
| 002859 |
| Anticholinergic therapies in the treatment of Parkinson's disease |
| 002863 |
| Amantadine and other antiglutamate agents |
| 002902 |
Elan D. Louis [États-Unis] ; Linda Winfield [États-Unis] ; Stanley Fahn [États-Unis] ; Blair Ford [États-Unis] | Speech dysfluency exacerbated by levodopa in Parkinson's disease |
| 002904 |
S. Thobois [France] ; E. Broussolle [France] ; L. Toureille [France] ; C. Vial [France] | Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy |
| 002919 |
William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie] | Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations |
| 002936 |
Marina Svetel [Serbie] ; Nadezda Sternic [Serbie] ; Sanja Pejovic [Serbie] ; Vladimir S. Kostic [Serbie] | Penicillamine-induced lethal status dystonicus in a patient with Wilson's disease |
| 002949 |
P. H. Gordon [États-Unis] ; S. J. Frucht [États-Unis] | Neuroleptic malignant syndrome in advanced Parkinson's disease |
| 002971 |
Birgit Högl [Autriche] ; Md. Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy: Placebo-controlled, polysomnographic case report |
| 002997 |
J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis] | Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature |
| 002A60 |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus) |
| 002A63 |
José A. Dominguez-Moran [Espagne] ; Juan M. Callejo [Espagne] ; Luis C. Fernandez-Ruiz [Espagne] ; Juan C. Martinez-Castrillo [Espagne] | Acute paroxysmal dystonia induced by fluoxetine |
| 002A78 |
C. W. Olanow [États-Unis] ; A. H. V. Schapira [Royaume-Uni] ; T. Roth [États-Unis] | Waking up to sleep episodes in Parkinson's disease |
| 002A91 |
Silvana Tesei [Italie] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Anna Zecchinelli [Italie] ; Claudio B. Mariani [Italie] ; Gianni Pezzoli [Italie] | Tolerability of paroxetine in Parkinson's disease : A prospective study |
| 002A96 |
Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa |
| 002B03 |
C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review |
| 002B17 |
T. A. Zesiewicz [États-Unis] ; M. Helal [États-Unis] ; R. A. Hauser [États-Unis] | Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's Disease |
| 002B22 |
N. A. Leopold [États-Unis] | Risperidone treatment of drug-related psychosis in patients with Parkinsonism |
| 002B23 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 002B36 |
R. A. Hauser [États-Unis] ; L. Gauger [États-Unis] ; W. M. Anderson [États-Unis] ; T. A. Zesiewicz [États-Unis] | Pramipexole-induced somnolence and episodes of daytime sleep |
| 002B69 |
Robert A. Hauser [États-Unis] ; Mervat N. Wahba [États-Unis] ; Theresa A. Zesiewicz [États-Unis] ; W. Mcdowell Anderson [États-Unis] | Modafinil treatment of pramipexole-associated somnolence |
| 002B76 |
S. Frucht [États-Unis] ; S. Fahn [États-Unis] ; S. Chin [États-Unis] ; V. Dhawan [États-Unis] ; D. Eidelberg [États-Unis] | Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration |
| 002B83 |
Doron Merims [Israël] ; Ronit Galili-Mosberg [Israël] ; Eldad Melamed [Israël] | Is there addiction to levodopa in patients with Parkinson's disease? |
| 002B87 |
Ruth H. Walker [États-Unis] ; Fabio O. Danisi [États-Unis] ; David M. Swope [États-Unis] ; Robert R. Goodman [États-Unis] ; Isabelle M. Germano [États-Unis] ; Mitchell F. Brin [États-Unis] | Intrathecal baclofen for dystonia: Benefits and complications during six years of experience |
| 002B91 |
T. E. Kimber [Australie] ; P. D. Thompson [Australie] | Increased blink rate in advanced Parkinson's disease : A form of 'off'-period dystonia? |
| 002B94 |
A. J. Manson [Royaume-Uni] ; E. Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease |
| 002C23 |
N. L. W. Keijsers [Pays-Bas] ; M. W. I. M. Horstink [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] ; J. I. Hoff [Pays-Bas] ; C. C. A. M. Gielen [Pays-Bas] | Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks |
| 002C38 |
David Devos [France] ; Luc Defebvre [France] ; Alain Destée [France] ; Jacques Caron [France] | Choreic movements induced by cibenzoline : An Ic class antiarrhythmic effect? |
| 002C45 |
H. Apaydin [Turquie] ; S. Ertan [Turquie] ; S. Özekmekci [Turquie] | Broad bean (Vicia faba) : A natural source of L-dopa : Prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations |
| 002C46 |
A. Rapaport [Israël] ; M. Sadeh [Israël] ; D. Stein [Israël] ; J. Levine [Israël] ; P. Sirota [Israël] ; T. Mosheva [Israël] ; S. Stir [Israël] ; A. Elitzur [Israël] ; I. Reznik [Israël] ; D. Geva [Israël] ; J. M. Rabev [Israël] | Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia |
| 002C47 |
D. Dressier [Royaume-Uni] ; G. Dirnberger [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni] ; A. Irmer [Allemagne] ; N. P. Quinn [Royaume-Uni] ; H. Bigalke [Allemagne] ; C. D. Marsden [Royaume-Uni] | Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay |
| 002C52 |
E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche] | Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease |
| 002C54 |
J. H. Friedman [États-Unis] ; S. A. Factor | Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease |
| 002C57 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
| 002C67 |
V. G. H. Evidente [États-Unis, Philippines] ; C. H. Adler [États-Unis] ; J. N. Caviness [États-Unis] ; J. G. Hentz [États-Unis] ; K. Gwinn-Hardy [États-Unis] | Amantadine is beneficial in restless legs syndrome |
| 002C84 |
| Dyskinesias |
| 002C86 |
G. Ebersbach [Autriche] ; M. Stöck [Autriche] ; J. Müller [Autriche] ; G. Wenning [Autriche] ; J. Wissel [Autriche] ; Werner Poewe [Autriche] | Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration |
| 002C87 |
E. S. Molho [États-Unis] ; S. A. Factor [États-Unis] | Worsening of motor features of Parkinsonism with olanzapine |
| 002D03 |
M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France] | The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease |
| 002D09 |
S. Spieker [Allemagne] ; P.-A. Löschmann [Allemagne] ; T. Klockgether [Allemagne] | The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations |
| 002D22 |
A. Churchyard [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Selegiline-induced postural hypotension in Parkinson's disease : A longitudinal study on the effects of drug withdrawal |
| 002D25 |
D. Mathen [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni] | SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia |
| 002D27 |
W. Ondo [États-Unis] ; MD [États-Unis] | Ropinirole for restless legs syndrome |
| 002D30 |
W. Meissner [Allemagne] ; T. Schmidt [Allemagne] ; A. Kupsch [Allemagne] ; T. Trottenberg [Allemagne] ; T. Lempert [Allemagne] | Reversible leucopenia related to olanzapine |
| 002D34 |
H. H. Fernandez [États-Unis] ; J. H. Friedman [États-Unis] ; C. Jacques [États-Unis] ; M. Rosenfeld [États-Unis] | Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease |
| 002D35 |
J. M. Brotchie [Royaume-Uni] ; S. H. Fox [Royaume-Uni] | Quantitative assessment of dyskinesias in subhuman primates |
| 002D37 |
H. H. Fernandez [États-Unis] ; J. H. Friedman [États-Unis] | Punding on L-dopa |
| 002D45 |
E. S. Molho [États-Unis] ; S. A. Factor [États-Unis] | Possible tardive dystonia resulting from clozapine therapy |
| 002D48 |
G. Lera [Argentine] ; J. Zirulnik [Argentine] | Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced Parkinsonism |
| 002D54 |
P. J. Bedard [Canada] ; P. J. Blanchet [Canada] ; D. Levesque [Canada] ; J.-J. Soghomonian [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; F. Calon [Canada] ; P. Falardeau [Canada] ; B. Gomez-Mancilla [Canada] ; J.-P. Doucet [Canada] ; G. S. Robertson [Canada] ; T. Dipaolo [Canada] | Pathophysiology of L-Dopa-induced dyskinesias |
| 002D58 |
M. G. Cerosimo [Argentine] ; F. Micheli [Argentine] | Paroxysmal dyskinesia and gonadal sex hormones |
| 002D88 |
F. Le Doze [France] ; M. Moulin [France] ; G.-L. Defer [France] | Meige's syndrome in a patient treated with ranitidine |
| 002D93 |
N. Giladi [Israël] ; E. Melamed [Israël] | Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism |
| 002D96 |
Olivier Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |
| 002D97 |
R. K. B. Pearce [Royaume-Uni] | L-dopa and dyskinesias in normal monkeys |
| 002E11 |
M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine] | GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine |
| 002E24 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 002E36 |
I. H. Richard [États-Unis] ; A. Maughn [États-Unis] ; R. Kurlan [États-Unis] | Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series |
| 002E37 |
E. A. Sekul [États-Unis] ; S. Kaminer [États-Unis] ; K. D. Sethi [États-Unis] | Digoxin-induced chorea in a child |
| 002E73 |
R. Ceravolo [Italie] ; S. Salvetti [Italie] ; P. Piccini [Royaume-Uni] ; C. Lucetti [Italie] ; G. Gambaccini [Italie] ; U. Bonuccelli [Italie] | Acute and chronic effects of clozapine in essential tremor |
| 002E74 |
M. Onofrj [Italie] ; A. Thomas [Italie] | Acetazolamide-responsive periodic ataxia induced by amiodarone |
| 002F07 |
J.-M. Gerard [Belgique] ; F. Delecluse [Belgique] ; Y. Robience [Belgique] | Theophylline-induced stuttering |
| 002F10 |
T. Van Laar [Pays-Bas] ; B. Van Hilten [Pays-Bas] ; C. Neef [Pays-Bas] ; A. W. F. Rutgers [Pays-Bas] ; S. Pavel [Pays-Bas] ; J. A. Bruijn [Pays-Bas] | The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease : A histologic study |
| 002F16 |
D. J. Burn [Royaume-Uni] ; A. Coulthard [Royaume-Uni] ; S. Connolly [Royaume-Uni] ; N. E. F. Cartlidge [Royaume-Uni] | Tardive diaphragmatic flutter |
| 002F17 |
P. Sachdev [Australie] | Tardive blepharospasm |
| 002F21 |
P. Van Den Munckhof [États-Unis] ; F. A. Lenz [États-Unis] ; T. N. Chase [États-Unis] ; L. V. Metman [États-Unis] | Square-wave action dystonia in Parkinson's disease |
| 002F23 |
M. S. Ledoux [États-Unis] ; L. J. Mcgill ; W. A. Pulsinelli ; R. F. Pfeiffer ; G. Deuschl [Allemagne] ; A. Siderowf [États-Unis] ; R. Kurlan [États-Unis] ; K. Sethi [États-Unis] | Severe bilateral tremor in a liver transplant recipient taking cyclosporine |
| 002F89 |
P. Krack [France] ; Pierre Pollak [France] ; P. Limousin [France] ; D. Hoffmann [France] ; A. Benazzouz [France] ; Alim-Louis Benabid [France] | Inhibition of levodopa effects by internal pallidal stimulation |
| 003034 |
J. Warren [Australie] ; P. Thompson [Australie] | Drug-induced supraglottic dystonia and spasmodic dysphonia |
| 003044 |
R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
| 003052 |
P. A. Lewitt [États-Unis] | Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease |
| 003054 |
I. M. Bronner [Pays-Bas] ; J. A. L. Vanneste [Pays-Bas] | Complex movement disorder associated with fluvoxamine |
| 003059 |
H. H. Fernandez [États-Unis] ; R. Durso [États-Unis] | Clozapine for dopaminergic-induced paraphilias in Parkinson's disease |
| 003065 |
J. F. Marti-Masso [Espagne] ; J. J. Poza [Espagne] | Cinnarizine-induced Parkinsonism : Ten years later |
| 003079 |
J. D. O'Sullivan [Australie] ; A. J. Hughes [Australie] | Apomorphine-induced penile erections in Parkinson's disease |
| 003082 |
T. Van Laar [Pays-Bas] ; G.-J. Lammers [Pays-Bas] ; R. A. C. Roos [Pays-Bas] ; J. J. Gerritsen [Pays-Bas] ; A. E. Meinders [Pays-Bas] | Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion |
| 003089 |
R. Kurlan [États-Unis] | Acute parkinsonism induced by the combination of a serotonin reuptake inhibitor and a neuroleptic in adults with Tourette's syndrome |
| 003096 |
R. A. Hauser [États-Unis] ; E. Molho [États-Unis] ; H. Shale [États-Unis] ; S. Pedder [États-Unis] ; E. E. Dorflinger [États-Unis] | A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients |
| 003140 |
A. Meyer-Lindenberg [Allemagne] ; B. Krausnick [Allemagne] | Tardive dyskinesia in a neuroleptic-naive patient with bipolar-I disorder : Persistent exacerbation after lithium intoxication |
| 003144 |
M. Poyurovsky [Israël] ; M. Schneidman [Israël] ; A. Weizman [Israël] | Successful treatment of fluoxetine-induced dystonia with low-dose mianserin |
| 003160 |
K. A. Gwinn [États-Unis] ; J. N. Caviness [États-Unis] | Risperidone-induced tardive dyskinesia and parkinsonism |
| 003177 |
MYUNG SIK LEE [Corée du Sud] ; CHUL HYOUNG LYOO [Corée du Sud] ; WON CHAN KIM [Corée du Sud] ; HO JEONG KANG [Corée du Sud] | Periodic bursts of rhythmic dyskinesia associated with spinal anesthesia |
| 003196 |
M. Gu [Royaume-Uni] ; M. T. Gash [Royaume-Uni] ; J. M. Cooper [Royaume-Uni] ; G. K. Wenning [Royaume-Uni] ; S. E. Daniel [Royaume-Uni] ; N. P. Quinn [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; A. H. V. Schapira [Royaume-Uni] | Mitochondrial respiratory chain function in multiple system atrophy |
| 003205 |
I. Ziv [Israël] ; R. Zilkha-Falb [Israël] ; D. Offen [Israël] ; A. Shirvan [Israël] ; A. Barzilai [Israël] ; E. Melamed [Israël] | Levodopa induces apoptosis in cultured neuronal cells : A possible accelerator of nigrostriatal degeneration in Parkinson's disease? |
| 003209 |
A. H. Rajput [Canada] ; M. E. Fenton [Canada] ; S. Birdi [Canada] ; R. Macaulay [Canada] | Is levodopa toxic to human substantia nigra? |
| 003216 |
S. Frucht [États-Unis] ; D. Eidelberg [États-Unis] | Imipenem-induced myoclonus |
| 003217 |
P. A. Lewitt [États-Unis] ; R. M. Trosch [États-Unis] | Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection |
| 003285 |
F. Ghika-Schmid [Suisse] ; J. Ghika [Suisse] ; P. Vuadens [Suisse] ; J. Bogousslavsky [Suisse] ; F. Regli [Suisse] ; P. A. Despland [Suisse] | Acute reversible myoclonic encephalopathy associated with fluoxetine therapy |
| 003291 |
A. Negrotti [Italie] ; S. Calzetti [Italie] | A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism |
| 003296 |
G. M. Petzinger [États-Unis] ; S. B. Bressman [États-Unis] | A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment |
| 003311 |
F. Stocchi [Italie] ; M. F. De Pandis [Italie] ; F. A. Delfino [Italie] ; T. Anselmo [Italie] ; D. Frongillo [Italie] | Transient atrial fibrillation after subcutaneous apomorphine bolus |
| 003359 |
M. Jauss [Allemagne] ; P. Krack [Allemagne] ; M. Franz [Allemagne] ; R. Klett [Allemagne] ; R. Bauer [Allemagne] ; B. Gallhofer [Allemagne] ; W. Dorndorf [Allemagne] | Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome |
| 003387 |
K. J. Bharucha [États-Unis] ; K. D. Sethi [États-Unis] | Complex movement disorders induced by fluoxetine |
| 003393 |
G. D. Ppodskalny [États-Unis] ; S. A. Factor [États-Unis] | Chorea caused by lithium intoxication : A case report and literature review |
| 003407 |
D.-E. Shan [Taïwan] ; S.-Y. Kwan [Taïwan] ; H.-H. Ho [Taïwan] ; M.-S. Su [Taïwan] | Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy |
| 003412 |
A. P. Sempere [Espagne] ; J. Duarte [Espagne] ; F. Garcia [Espagne] ; C. Cabezas [Espagne] ; F. Coria [Espagne] ; L. E. Claveria [Espagne] | An estimate of the risk of movement disorders associated with the chronic use of clebopride |
| 003416 |
P. J. Blanchet [États-Unis] ; L. V. Metman [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Acute pharmacologic blockade of dyskinesias in Parkinson's disease |
| 003427 |
G. Pezzoli [Italie] ; A. Antonini ; S. Barbieri [Italie] ; M. Canesi [Italie] ; L. Perbellini ; A. Zecchinelli [Italie] ; C. B. Mariani [Italie] ; A. Bonetti [Italie] ; K. L. Leenders | n-Hexane-induced Parkinsonism : pathogenetic hypotheses |
| 003442 |
K. J. Bharucha [États-Unis] ; K. D. Sethi | Tardive tourettism after exposure to neuroleptic therapy |
| 003449 |
J. C. Garcia-Monco [Espagne] ; A. Padierna ; M. G. Beldarrain | Selegiline, fluoxetine, and depression in Parkinson's disease |
| 003507 |
J.-L. Montastruc [France] ; N. Fabre [France] ; O. Blin [France] ; J.-M. Senard [France] ; Olivier Rascol [France] ; A. Rascol [France] | Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study |
| 003512 |
R. K. B. Pearce [Royaume-Uni] ; M. Jackson [Royaume-Uni] ; L. Smith [Royaume-Uni] ; P. Jenner ; C. D. Marsden | Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus) |
| 003518 |
M. F. Gordon [États-Unis] ; R. I. Abrams ; D. B. Rubin ; W. B. Barr ; D. D. Correa | Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus |
| 003530 |
M. T. Dotti [Italie] ; A. Federico | Amiodarone-induced Parkinsonism : a case report and pathogenetic discussion |
| 003532 |
A. Priori [Italie] ; L. Bertolasi ; A. Berardelli ; M. Manfredi | Acte dystonic reaction to ectasy |
| 003566 |
K. Nakashima [Japon] ; M. Shimoda ; N. Kuno ; K. Takahashi | Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson's disease |
| 003577 |
E. C. Lauterbach [États-Unis] | Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease |
| 003589 |
A. P. Sempere [Espagne] ; J. Duarte [Espagne] ; J. M. Palomares ; F. Coria ; L. E. Claveria | Parkinsonism and tardive dyskinesia after chronic use of clebopride |
| 003599 |
J. M. Olive [Espagne] ; L. Masana ; J. Gonzalez | Meperidine and reversible parkinsonism |
| 003602 |
R. Marconi [France] ; D. Lefebvre-Caparros ; A.-M. Bonnet [France] ; M. Vidailhet [France] ; B. Dubois [France] ; Yves Agid [France] | Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology |
| 003639 |
J. Kulisevsky [Espagne] ; M. Lima De Freitas ; L. Barraquer-Bordas | Bilateral akinesia in drug-induced parkinsonism after a subthalamic lesion |
| 003655 |
R. A. Hauser [États-Unis] ; C. W. Olanow | orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease |
| 003659 |
M. De Mari [Italie] ; R. De Blasi ; P. Lamberti ; A. Carella ; E. Ferrari | Unilateral pallidal lesion after acute disulfiram intoxication: a clinical and magnetic resonance study |
| 003663 |
C. G. Garner [Allemagne] ; A. Straube ; T. N. Witt ; T. Gasser ; W. H. Oertel | Time course of distant effects of local injections of botulinum toxin |
| 003669 |
A. J. Stoessl [Canada] ; E. Polanski ; H. Frydryszak | The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia |
| 003673 |
P. Sachdev [Australie] | Tardive and chronically recurrent oculogyric crises |
| 003676 |
S. B. Blunt [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine |
| 003696 |
A. Feve [France] ; B. Angelard [France] ; G. Fenelon [France] ; M. Logak [France] ; A. Guillard [France] ; J. Lacau Saint-Guily | Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin |
| 003697 |
M. B. Harrison [États-Unis] ; G. R. Lyons ; E. R. Landow | Phenytoin and dyskinesias : a report of two cases and review of the literature |
| 003698 |
F. Javier Jimenez-Jimenez [Espagne] ; F. Cabrera-Valdivia ; L. Ayuso-Peralta ; J. Tejeiro ; A. Vaquero ; E. Garcia-Albea | Persistent parkinsonism and tardive dyskinesia induced by clebopride |
| 003699 |
P. A. Lewitt [États-Unis] ; A. Walters ; W. Hening ; D. Mchale | Persistent movement disorders induced by buspirone |
| 003711 |
A. Ferbert [Allemagne] ; R. Biniek [Allemagne] ; J. Kindler ; N. Maurin | Myoclonus and tremor induced acutely by administration of tumor necrosis factor in a patient with Ehlers-Danlos syndrome |
| 003753 |
B. Pardo [États-Unis] ; M. A. Mena [États-Unis] ; S. Fahn ; J. Garcia De Yebenes | Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line |
| 003774 |
M. Stacy [États-Unis] ; Joseph Jankovic [États-Unis] | Tardive tremor |
| 003778 |
J. H. Friedman [États-Unis] | Rubral' tremor induced by a neuroleptic drug |
| 003779 |
I. J. Mitchell [Royaume-Uni] ; A. R. Crossman ; U. Liminga ; P. Andren ; L. M. Gunne | Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey |
| 003787 |
L. G. Miller [États-Unis] ; Joseph Jankovic [États-Unis] | Persistent dystonia possibly induced by flecainide |
| 003791 |
P. Montagna [Italie] ; A. S. Gabellini ; L. Monari ; E. Lugaresi | Parkinsonian syndrome after long-term treatment with clebopride |
| 003794 |
M. A. Mena [Espagne] ; B. Pardo ; M. J. Casarejos ; S. Fahn ; J. G. De Yebenes | Neurotoxicity of levodopa on catecholamine-rich neurons |
| 003799 |
M. R. Luquin [Espagne] ; O. Scipioni ; J. Vaamonde ; O. Gershanik ; J. A. Obeso | Levopoda-induced dyskinesias in Parkinson's disease : clinical and pharmacological classification |
| 003800 |
J.-F. De Saint Victor [France] ; C.-L. Gervason | Levopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine |
| 003807 |
S. Przedborski [Belgique] ; A. Liard ; J. Hildebrand | Induction of mania by apomorphine in a depressed Parkinsonian patient |
| 003812 |
M. J. Steiger [Royaume-Uni] ; M. Pires ; F. Scaravilli ; N. P. Quinn ; C. D. Marsden | Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration |
| 003814 |
A. Guala [Italie] ; D. Mittino ; P. Fabbrocini ; T. Ghini | Familial metoclopramide-induced dystonic reactions |
| 003823 |
C. E. Clarke [Royaume-Uni] ; J. M. Bamford ; A. House | Dyskinesia in Creutzfeldt-Jakob disease precipitated by antidepressant therapy |
| 003848 |
R. C. Peatfield ; B. R. Boothman | Transient myoclonus after exposure to oven cleaner |
| 003852 |
M. J. Steiger ; N. P. Quinn ; C. D. Marsden | Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease |
| 003865 |
M. J. Steiger ; N. P. Quinn ; B. Toone ; C. D. Marsden | Off-period screaming accompanying motor fluctuations in Parkinson's disease |
| 003893 |
M. J. Merello ; M. A. Nogues ; R. C. Leiguarda ; C. Lopez Saubidet | Dystonia and reflex sympathetic dystrophy induced by ergotamine |
| 003894 |
J. K. Krauss [Allemagne] ; M. Mohadjer ; A. K. Wakhloo ; F. Mundinger | Dystonia and akinesia due to pallidoputaminal lesions after disulfiram intoxication |
| 003895 |
U. Bonuccelli ; A. Nocchiero ; A. Napolitano ; A. M. Paoletti ; G. B. Melis ; G. U. Corsini ; A. Muratorio | Domperidone-induced acute dystonia and polycystic ovary syndrome |
| 003919 |
A. Achiron ; E. Melamed | Tardive eating dystonia |
| 003921 |
L. G. Miller ; Joseph Jankovic [États-Unis] | Sulpiride-induced tardive dystonia |
| 003928 |
K. D. Sethi ; D. C. Hess ; R. J. Harp | Prevalence of dystonia in veterans on chronic antipsychotic therapy |
| 003930 |
K. D. Sethi ; A. Hitri ; B. I. Diamond | Phenytoin potentiation of neuroleptic-induced dyskinesias |
| 003936 |
M. E. Rodriguez ; M. R. Luquin ; G. Lera ; G. Delgado ; J. M. Salazar ; J. A. Obeso | Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion |
| 003939 |
M. A. Menza ; J. Sage ; E. Marshall ; R. Cody ; R. Duvoisin | Mood changes and on-off phenomena in Parkinson's disease |
| 003943 |
S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Induction of chorea and dystonia in parkinsonian primates |
| 003972 |
A. R. Crossman | A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment |
| 003987 |
R. E. Burke ; UN JUNG KANG ; Joseph Jankovic [États-Unis] ; L. C. Miller ; S. Fahn | Tardive akathisia: an analysis of clinical features and response to open therapeutic trials |
| 003991 |
U. Andersson ; J.-E. Haggstrom ; E. D. Levin ; U. Bondesson ; M. Valverius ; L. M. Gunne | Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia |
| 003998 |
F. E. Micheli ; M. M. Fernandez Pardal ; R. Giannaula ; M. Gatto ; I. Casas Parera ; G. Paradiso ; M. Torres ; R. Pikielny ; J. Fernandez Pardal | Movement disorders and depression due to flunarizine and cinnarizine |
| 003A00 |
S. Gimenez-Roldan ; D. Mateo ; M. Martin | Life-threatening cranial dystonia following trihexyphenidyl with drawal |
| 003A04 |
W. S. Metzer ; J. E. O. Newton ; R. W. Steele ; M. Claybrook ; S. R. Paige ; D. E. Mcmillan ; S. Hays | HLA Antigens in drug-induced Parkinsonism |
| 003A07 |
E. Pourcher ; A.-M. Bonnet ; J. Kefalos ; B. Dubois ; Yves Agid [France] | Effects of etybenzatropine and diazepam on Levodopa-induced diphasic dyskinesias in Parkinson's disease |
| 003A08 |
E. Mohr ; G. Fabbrini ; J. Williams ; J. Schlegel ; C. Cox ; P. Fedio ; T. N. Chase | Dopamine and memory function in Parkinson's disease |
| 003A11 |
MOHAMMAD REZA SAMIE ; A. K. Ashton | Choresathetosis induced by cyproheptadine |
| 003A15 |
M. Deahl | Betel nut-induced ectrapyramidal syndrome: an unusual drug interaction |
| 003A16 |
L. E. Adler ; M. Pecevich ; H. Nagamoto | Bereitschaftspotential in tardive dyskinesia |
| 003A21 |
R. F. Pfeiffer ; E. L. Sucha | "On-off"-Induced lethal hyperthermia |
| 003A32 |
S. K. Singh ; Joseph Jankovic [États-Unis] | Tardive dystonia in patients with Tourette's syndrome |
| 003A47 |
D. Dung Truong ; J. Garcia De Yebenes ; G. Pezzoli ; V. Jackson-Lewis ; S. Fahn | Glycine involvement in DDT-induced myoclonus |
| 003A64 |
R. L. Albin ; A. K. Silverman ; C. N. Ellis ; J. J. Voorhees ; J. W. Albers | A new syndrome of axial muscle rigidity associated with etretinate therapy |
| 003A73 |
F. A. Luque ; J. B. Selhorst ; P. Petruska | Parkinsonism induced by high-dose cytosine arabinoside |
| 003A75 |
M. R. Samie | Neuroleptic malignant-like syndrome induced by metoclopramide |
| 003A77 |
M. R. Samie ; M. A. Dannenhoffer ; S. Rozek | Life-threatening tardive dyskinesia caused by metoclopramide |
| 003A88 |
H. L. Klawans | Dystonia and tremor following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin |
| 003A96 |
F. Grandas ; N. Quinn ; P. Critchley ; A. Rohan ; C. D. Marsden ; S. M. Stahl | Antiparkinsonian activity of a single oral dose of PHNO |
| 003A98 |
M. Nomoto ; P. D. Thompson ; M. P. Sheehy ; N. P. Quinn ; C. D. Marsden | Anticholinergic-induced chorea in the treatment of focal dystonia |
